EMA’s PRIME Scheme and Clinical Trial Implications
EMA’s PRIME Scheme and Clinical Trial Implications Clinical Trial Implications of EMA’s PRIME Scheme The PRIority MEdicines (PRIME) scheme, launched by the European Medicines Agency (EMA) in 2016, provides early and enhanced regulatory support for medicines that address unmet medical needs. By offering scientific advice, early dialogue, and expedited review pathways, PRIME facilitates faster patient…
Read More “EMA’s PRIME Scheme and Clinical Trial Implications” »